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Rolipram is a potential antidepressant which did
not seem to exert a strong direct interaction with
adrenoceptors in vitro as the binding of [3H]PAC and
[3H]DHA to alpha-2 and beta-adrenoceptors respectively
were not affected by 100 uM of rolipram. The same
concentration did, however, exert a slight inhibition
(10%) on the binding of [3H]WB 4101 to alpha-1
adrenoceptors.
The levels of beta, alpha-1 and alpha-2
adrenoceptors as well as the noradrenal ine- and
isoproterenol-stimulated adenylate cyclase activities
in rat brains and submandibular glands were examined
after chronic rolipram (10 mg/kg, i.p.) or desipramine
(10 mg/kg, i. p.) treatment. Scatchard analysis of
[3H]dihydroalprenolol ([3H]DHA) binding to
beta-adrenoceptors.in the cerebral cortex membrane of
rats treated with racemic rolipram for 11 and 17 days
revealed that neither the number (Bmax) nor the
affinity (Kd) of beta- adrenoceptors was changed. In
contrast, chronic treatment with a classical tricyclic
antidepressant, desipramine significantly decreased
(30%) the Bmax values of [3H]DHA binding after 11
and 17 days of treatment. The same period of
desipramine treatment, however, did not alter the
2affinity of beta-adrenoceptors for [3H] DHA
Niether the NE- nor the isoproterenol- stimulated
activities of adenylate cyclase was changed by chronic
rolipram treatment. However, in parallel experiments,
these stimulated responses to the beta-adrenergic
agonists were down-regulated (approx. 30%) after 17
days of desipramine treatment. Both rolipram and
desipramine treatment did not alter the basal activity
of adenyalte cyclase.
The alpha-1 adrenoceptors in rat cerebral cortex
membranes labelled with [3H]WB 4101 were not altered
by chronic treatment with either rolipram or
desipramine. The cortical alpha-2 adrenoceptors
labelled with [3H]PAC were also unchanged both after
11 and 17 days of rolipram treatment. On the other
hand, a significant decrease (20%) of the alpha-2
adrenoceptors was found after 17 days of desipramine
treatment.
Similar to the results in the cerebral cortex,
chronic rolipram treatment did not change
significantly the level of beta-adrenoceptors in the
rat submand ibu l ar gland membranes, whereas a
significant decrease (approx. 30%) was observed after
311 and 17 days of desipramine treatment. The level of
alpha-1 adrenoceptors in the rat submandibular gland
membranes labelled with [3H]WB 4101 was unaltered
after 11 days of desipramine and rol ipram treatment,
however, longer treatment with rolipram (17 days) did
reduce the level of [3H]WB 4101 binding. The level of
alpha-2 adrenoceptors labelled with [3H]PAC was not
changed after 11 days of rolipram and desipramine
treatment.
In conclusion, after chronic rolipram treatment,
both the beta-adrenoceptor and NE-linked adenylate
cyclase activity in the rat cerebral cortex were
unchanged. In contrast, chronic desipramine treatment
down-regulated both parameters. A similar decrease of
beta-adrenoceptor was observed in rat submandibular
gland with chronic desipramine treament, whereas
rolipram did not alter the level of beta-adrenoceptors
in this tissus either. Differential regulation of the
alpha-1 adrenoceptors was also observed in the rat
cerebral cortex versus the submandibular glands as
they were decreased (30- 40%) in the submandibular
gland but remained unchange in the cerebral cortex
after 17 days of rolipram treatment. A decrease in the
cerebral cortex alpha-2 adrenoceptors was observed
after desipramine but not rolipram treatment.
1,1)Background;
Rolipram is a potent cAMP phosphodiesterase
inhibitor belonging to the dialkoxyphenyl substituted
pyrrolidones (Schultz et al.. 1986). Its
antidepressant potentialities have been suggested on
the basis of animal (Wachtel, 1982; Przegalinski, et
al., 1983) and clinical studies, including a
preliminary open phase II (Laemmel et al.. 1983;
Zeller et al., 1984; Horowski et al.. 1985) and a
recent double blind controlled studies in patients
with endogenous depression (Wachtel et al., 1985). It
A
is chemically and biochemically different from the
classical antidepressants which are .either monoamine
oxidase inhibitors or biogenic amine uptake
inhibitors. In addition, rolipram is characterized by
having a 1)rapidly acting antidepressive action; 2)a
high therapeutic potency and the lack of
cardiotoxicity and anticholinergic side effects. Thus,
a detail investigation of its neurochemical effects
may provide new insights into the etiology of
depression and new avenues for antidepressive
treatment.
There are 2 major objectives in the present
study 1)to compare the effects of chronic rolipram
treatment on the central beta—adrenoceptors and the
receptor coupled-adenylate cyclase in rats with that
of a classical antidepressant, desipramine and 2)to
study and compare the effects of chronic rolipram and
desipramine treatment on the adrenoceptors in rat
submandibular glands.
1.2)Catecholamine hypothesis of affective disorder:
Even though antidepressants are effective in the
treatment of affective disorders, the biochemical
mechanism that responsible for their therapeutic
effects has remained unclear. With the advent of the
A
catecholamine hypothesis of affective disorders in
1965 (Schildkraut, 1965), their effects on the
s
noradrenergic transmission has dominated the research
strategies on affective disorder for the last 20
years. This hypothesis suggests that a reduced
noradrenergic transmission is associated with
depression whereas an increased noradrenergic
transmission elevates mood. Such hypothesis is based
on the acute pharmacological effects elicited by
various antidepressants. For instance, the tricyclic
antidepressants can increase the level of
norepinephrine (NE) and serotonin (5—HT) through
inhibition of the reuptake of NE and 5-HT while the
monoamine oxidase inhibitors (MAOI) block the activity
of the monoamine oxidase which degrades both NE and
5-HT. Consequently, it is believed that the
therapeutic effects of antidepressants can be
attributed to their ability to increase norepinephrine
at central synapses.
However the concept of monoamine deficiency is
currently being regarded as an oversimplification, as
:l)the blockade of NE and or 5-HT uptake by tricyclic
antidepressants is rapid, whereas the therapeutic
effects of these antidepressants takes several weeks
to develop (Lahti et al., 1971); 2)iprindole (Lahti et
al., 1971) and mianserine (Leonard, 1974; Goodlet, et
al., 1977) which are essentially devoid of effects on
monoamine oxidase and monoamine uptake in vivo are yet
efficacious antidepressants (Zis et al., 1979);
3)drugs such as cocaine and amphetamine which block
monoamine uptake (Glowinski et al., 1966) fail to
exhibit antidepressant effects (Post et al., 1974).
Two discoveries in the second half of the 1970's
sparked off a shift in research emphasis from acute
presynaptic to chronic postsynaptic receptor mediated
events: l)a subsensitivity of noradrenoceptor function
has been shown to occur after chronic but not acute
administration of various antidepressants and
electroconvulsive shock treatment (ECT) (Vetulani et
1., 1975); 2)the noradrenergic subsensitivity in the
brain following chronic antidepressant treatment has
been related to a decrease in the density of
beta-adrenoceptors as determined by radioligand
binding assays using [3H]dihydroalprenolol (Banerjee
et al.. 1977).
1.3Noradrenergic and serotonergic innervation in the
rat brain:
1.3.1 Noradrenergic innervations:
Several noradrenergic pathways in the rat brain
are well delineated. All noradrenergic cell bodies are
confined to the hind brain, in thepon and medulla.
The Al, A2, and A5 cells are located in the ventral
medulla and they project axons both caudally to the
spinal cord and rostrally to the forebrain. The
clearest cell body grouping is the locus coeruleus,
which is situated in the floor of the fourth
ventricle. It constitutes the A6 cells, with the A7
cells ventrolaterally and the A4 cells caudally
located to it.
The locus coeruleus contains the most abundant
noradrenergic cell population and is responsible for
noradrenergic innervation of all the cortices,
geniculate bodies, colliculi, thalamus and
hypothalamus. The rostral projection is divided into
the dorsal and ventral branches. The dorsal pathway
arises in the locus coeruleus and projects
ventrolaterally to the central grey area. Its main
component runs in the medial forebrain bundle to
innervate all the cortices, thalamus, geniculate
bodies, colliculi, habenula, some hypothalamic nuclei
and olfactory bulb. The ventral pathway arises from
the Al, A5 and A7 cell bodies and runs through the
medullary reticular formation, the pons and
mesencephalon, gradually overlapping with the dorsal
A
bundle. Then it extends through the cuneate nucleus
and the A8 cell region to innervatexthe septal area,
preoptic area, hypothalamus, periventricular area,
mammiallary bodies and substantia nigra. The A4 cells
probably project to the cerebellum. In the cerebellar
cortex, the NE input from the locus coeruleus synapse
with the purkinje cells; in the hippocampus and
dentate gyrus, the pyramidal neurons are the recipient
eelIs.
1.3.2)Serotonergic innervations:
The serotonergic pathways are originated from the
cell bodies situated mainly in the midline raphe
nuclei. The rostral projections are not clearly known
but appear to be diffuse innervation to the forebrain,
possibly through a projection in the medial forebrain
bundle. Axonal projections from the raphe also extend
to the limbic system (hippocampus and amygdala),
lateral geniculate and superior colliculus. Another
pathway runs caudally from the midline regions in the
brain stem to innervate the spinal cord.
1.3.3)Spatial relation between the 2 pathways:
The terminal fields of the serotonergic
projections in the cortex coincide more or less with
those of the noradrenergic projections (Sulser e£
al., 1984).
1.4)Nature of adrenoceptor:
1. 4.1)Classification of adrenoceptor:
Adrenoceptors have been classified as alpha and
beta-subtypes on the basis of their distinct
pharmacological profiles in peripheral organ systems
(Ahlquist, 1948). Beta-adrenoceptors are selectively
stimulated by isoproterenol but blocked by either
alprenolol, propranolol or hydroxybenzylpindolol.
Alpha—adrenoceptors are much less sensitive to the
beta-adrenoceptor agents, however, they can be
blocked by phentolamine. Subsequently, each
adrenoceptor subtype is further subdivided into 2
unique species: beta—1 and 2; alpha-1 and 2.
The subdivision for beta-adrenoceptors (Lands et
aJL_, 1967) is based on the differential stimulatory
potency of epinephrine and norepinephrine and the
selective blocking effects of antagonists: beta-1
adrenoceptor have equal affinity for E and NE,
whereasd the beta-2 subtype is more sensitive to E;
beta-1 receptors are selectively blocked by atenolol
and metaprolol whereas butoxamine is the selective
antagonist for beta-2 subtype.
Alpha-adrenoceptors are subdivided by their
A
pharmacology and functions (Langer, 1974, 1980): for
alpha-1 adrenoceptors, both prazosin and WB-4101 are
selective antagonists; at alpha-2 adrenergic sites,
piperoxan and yohimbine are selective antagonists,
while clonidine and other imidazolines are selective
agonists (Synder, 1980)
1.4.2)Adrenoceptor and adenylate cyclase:
In the central nervous system (CNS), considerable
evidence show that NE stimulates the accumulation of
cAMP in many brain areas and in the spinal cord (Jones
et al.. 1980 a, b, c) by activation of both alpha- and
beta-adrenoceptors (Daly, 1975; Schultz and Daly,
1973). Both beta-1 and beta-2 adrenoceptors appear to
be positively coupled to the adenylate cyclase and
increase cAMP formation in virtually every regions of
the brain (Kant et al., 1981).
In contrast, the exact association of
alpha-adrenoceptors with adenylate cyclase has been a
difficult problem to settle. In the cerebral cortical
slices, stimulation of alpha-1 adrenoceptors appear to
be involved in cAMP production. The alpha adrenoceptor
agonists seem to increase cAMP generation indirectly
by the augmentation of beta-adrenergic, histamine and
adenosine receptor-mediated stimulation of adenylate
cyclase (Daly et al.. 1980). Their augmenting effects
vary considerably in different brain regions (Daly et
al., 1981): in cerebral cortex the alpha-adrenergic
response is almost completely dependent on adenosine
but such dependence is diminished or absent in other
regions of the brain.
Opposite to the stimulatory effects of
alpha-adrenoceptors to cAMP generation in many brain
areas, the activation of alpha-2 adrenoceptors
inhibits cAMP formation in cultured glial cells and in
the neuroblastoma X glioma cell line NG 108 15 (Kahn
et al, 1982). Beyond this, there is no evidence of
either subtypes of alpha—adrenoceptor being negatively
coupled to adenylate cyclase in the CNS.
n top of the uncertainty in the coupling, the
physiological significance of alpha—adrenoceptor in
the modulation of cAMP levels is quite unclear.
In peripheral tissues, the alpha-2 adrenoceptor
appears to be negatively coupled to adenylate cyclase
in many systems studied (Garcia-Sains et al., 1980).
1.4.3)Other functions associated with alpha-1 and
alpha-2 adrenocptors:
Functionally, presynaptic alpha-2 adrenoceptor has
A
been shown to modulate the presynaptic content of NE
via the feedback inhibition of NE release in both the
peripheral and central nervous system (Westfall, 1977;
Langer, 1980). Alpha-1 but not alpha-2 acivation has
been shown to be associated with phosphoinositide
hydrolysis in the rat brain and a number of peripheral
tissues (Vi1lalobos-Molina et al., 1982; Garcia-Sainz
et al.. 1980). It has been proposed that the
phosphoinositide hydrolysis may be responsible for the
transduction of receptor-mediated information across
the cell membrane by regulation of Ca2+ entry (Takai
et al., 1979; Berridge, 1981).
1.5) Characteristics Ol the bet.ft-arirftnnnptrr moddI r)
adenylate cyclase:
1.5.1)Structure of the beta-adrenoceptor coupled
adenylate cyclase system:
Structurally, the adrenoceptor-coupled adenylate
cyclase system consists of at least three separate
protein components in the plasma membrane: the
beta-adrenoceptor, the guanine nucleotide binding
protein and the adenylate cyclase.
At the molecular level, beta-adrenoceptor is a
transmembrane glycoprotein (Lefkowits et al., 1983)
with the receptor subtypes differing in molecular
weight (the molecular weights of beta-1 and beta-2
subunit range from 40,000-43,000 and 62,000-67,000
respectively). The Gs (or Ns) protein that embedded in
the inner portion of the plasma membrane is composed
of 3 subunits (Hildebrandt et al., 1984): alpha-s,
beta and gamma-subunits. The alpha-s bears the GTP
binding site which is the target for ADP ribosylation
by NAD+ and cholera toxin while the other 2 subunits
are tightly associated with each other. In addition,
Gs appears to possess GTPase activity. The adenylate
cyclase is a single transmembrane polypeptide carrying
its catalytic site at the inner surface of the
membrane (Pfeuffer et al., 1985)
1.5. 2)Characteristios q£ the central
beta-adrenocentor:
With reference to the distribution,
beta-adrenoceptors are widely distributed in the brain
but their density varies over a 45-fold range. The
highest density occurs in the striatum, frontal cortex
and dentate gyrus. The lowest density occurs in the
optic tract and corpus callosum (Leibowits et
al.,1982). In addition, their distribution bear no
apparent relationship to the catecholamine content of
the particular brain regions: cerebral cortex and
caudate nucleus have a high and low content of NE
respectively, but they are equally abundant in their
beta-adrenoceptors.
Both beta-adrenoceptor subtypes coexist in the
rat brain, but their exact cellular distribution has
not been clarified. It seems that they exist on
different cell types, but they may also present on the
same cell type (Minneman et al., 1979; Minneman
Molinoff, 1979). It is proposed that a)beta-l subtype
is associated with the heterogenously distributed
populations of neurons in the rat cerebral cortex
(Minneman et al., 1979; Minneman Molinoff, 1979),
b)beta-2 subtype may be associated with more
homogenously distributed nonneuronal cells such as the
microvasculature and filial cells. Such proposed
pattern of distribution is based on the following:
a)manipulations (chronic treatment with desipramine
and destruction of noradrenergic neurons by 6-OHDA)
which affect neuronal activity in the rat cerebral
cortex can result in compensatory changes in the
density of beta-1 but not the beta-2 subtype (Minneman
et al., 1979; Minneman Molinoff, 1979); b)depending
on the age of the rat, the relative density of beta-2
subtype is similar in both cerebral cortex and
cerebellum whereas the density of beta-1 subtype is
100 fold greater in the cerebral cortex than in
cerebellum (Minneman et al.. 1979; Pittman et al..
1980). However, there is exception to the proposed
pattern' of distribution, for instance, both receptor
subtypes coexist in C6 cloned glioma cell line
(Homburger et al., 1981) that are coupled to the
adenylate cyclase (Ebersolt et al.. 1981).
Concerning the regulation of beta adrenoceptors,
results tend to suggest that cerebral cortical beta-1
receptors are more sensitive to the changes in NE
activity and they are probably regulated independently
of the beta-2 subtype. Several investigators (Minneman
et al, 1979; U'Prichard et al., 1979; Minneman
Molinoff, 1979) have reported that the loss of NE
innervation to the cerebral cortex significantly
elevated the density of the beta-1 subtype;
conversely, augmentation of NE transmission (as occurs
after chronic desipramine treatment) specifically
decreases the beta-1 subtype. This selective
regulation may be related to the low affinity of
beta-2 adrenoceptor for NE and the lack of a direct
noradrenergic input onto the beta-2 receptors (Pittman
et al., 1980)
1.5.3)Sensitivity of the NE-resnonsive cAMP generating
system:
1.5. 3a)Supersensitivity or up-regulation of the
system:
In the rat cerebral cortex, increases in the
sensitivity of beta-adrenoceptors to stimulation by
agonists can be induced by a decreased NE input. A
decrease in NE input can, in turn, be induced
chemically (6-hydroxydopamine and reserpine) or
surgically (medical forebrain bundle lesions). The
supersensitivity (Kalisker et_al., 1973; Sporn et al.,
1976) is characterized by l)an apparent loss of
presynaptic reuptake sites for NE; 2)an increase in
the density of postsynaptical beta-adrenoceptors
3)the exhibition of specific homologous
supersensitivity (i.e. the up-regulation of the
NE-reoeptor-eoupled adenylate cyclase system is
specific for the beta-agonists only) (Vetulani and
Sulser, 1976).
1.5. 3b)Down-regulation or subsensitivitv of the
system:
The down-regulation (Harden et al.. 1983) of
beta-adrenoceptor coupled adenylate cyclase is a
typical homologous desensitization (Su et al.,
1980). It means that the attenuation of the response
towards repeated challenges by beta-agonists does not
A
affect the ability of other receptors to exert their
action via the adenylate cyclase.
The time course of desensitization is
characterized by 2 phases of events (Harden, 1983; Su
and Perkins, 1980 a,b): a faster onset of homologous
desensitization followed by a slower onset of
nonspecific heterologous desensitization.
In the first phase, the beta-adrenoceptors become
functionally uncoupled from the adenylate cyclase
system without any noticeable change in the function
of Gs or adenylate cyclase. The uncoupled form of the
beta-adrenoceptor is characterized by l)the inability
to activate adenylate cyclase; 2)its diminished
affinity towards beta-agonists but not to
beta-antagonists; 3)the inability of guanyl
nucleotides to modify its affinity towards
beta-agonists. The extent of desensitization depends
on the nature of agonists: a full agonist induces a
full measure of uncoupling whereas a partial agonist
induces only a partial uncoupling. The loss of surface
beta-adrenoceptors is reversible, and on agonist
withdrawal, beta-adrenoceptors reappear (Harden, 1983)
The second phase results after a prolonged
exposure of the receptors to beta-agonists, in which
the beta-adrenoceptors are irreversibly lost from
membrane surface and the adenylate cyclase becomes
refractory to stimulation by other receptors. This
type of desensitization is the nonspecific
heterologous desensitization (Su et al., 1980a). The
nonspecific desensitzation probably affects Gs (the
common denominator for all adenylate cyclase
stimulatory receptors) or the protein domains of other
receptors that interacts with Gs. Restoration of the
original number of receptors subsequent to down
regulation requires the biosynthesis of new receptors.
1» 6)The—use of rat submandibular salivary glands tn
study the Pharmacology of adrenergic systems:
The gland exhibits 3 subtypes of adrenoceptors:
alpha-1, alpha-2 and beta-1 (Bylund et al.. 1981). The
amount, the rate of secretion, and the composition of
saliva are modified by both sympathetic (alpha-1,
alpha-2 and beta-1 adrenoceptors) and parasympathetic
(muscarinic cholinergic) receptor systems.
Biochemically, several measurable parameters are
governed by different adrenoceptors: 1)alpha-1
stimulation initiates potassium release (Martinez et
al., 1976; Spearman and Pritchard, x1977); 2)alpha-2
stimulation results in the inhibition of
norepinephrine release (Filinger et al., 1978);
3)beta-1 stimulation mediates an activation of the
adenylate cyclase and an increase in the level of cAMP
(Babad et al., 1967; Butcher et al., 1975).
Physiologically, stimulation of different
adrenoceptors elicits saliva of different quantity and
quality. Stimulation of alpha adrenoceptor results in
the formation of a moderate amount of saliva rich in
electrolytes, whereas stimulation of beta adrenoceptor
causes the secretion of a scanty volume of saliva rich
in protein (Martinez et al., 1975; Young and van
Lermep, 1979)
Functionally, the submandibular adrenoceptors are
very responsive to changes in the levels of
catecholamines. For instance, after chronic reserpine
treatment, the density of alpha-2 (Bylund et al..
1980) and beta-adrenoceptors (Bylund et al., 1981)
increases by 10 and 2 fold respectively.
With reference to beta-adrenoceptor, the
submandibular gland has the advantage of bearing
predominantly the beta-1 subtype (Bylund et al.,
1981). Thus, investigation of the pharmacological
characteristics of beta-1 adrenoceptor is more
convenient in the submandibular gland as compared to
tissues which contain a mixed population of beta-1 and
beta-2 adrenoceptors such as in the lung and heart.
As compared with cerebral cortex, the
characteristics of beta-adrenoceptor are similar in
the following aspects: l)both have beta-1 adrenergic
subtype as the predominant beta-adrenoceptor;
2)pharmacologically, after chronic reserpine
treatment, both the number of beta-1 adrenoceptor and
the isoproterenol—stmulated adenylate cyclase activity
are up-regulated; 3)a similar up-regulation is
reported after noradrenergic denervation (Sporn
al., 1976; Skolnick et al., 1978; Arnett et al..
1979).
1.7)Sensitivity changes of alpha-adrenoceptors after
chronic antidenressive treatments:
Antidepressant treatments, if administered on a
clinically relevant time basis have been reported to
change the number andor the function of alpha-1 and
alpha-2 adrenoceptors. However, these changes are
varied among different reports and do not appear to be
A
a common consequence of antidepressant treatments
(Charney et al.» 1981; Sugrue, 1982).
1. 7. la)Changes in alpha-1 adrenoceptor:
Contrasting results have been reported for the
sensitivity of central alpha-1 adrenoceptors after
chronic administration of a variety of
antidepressants. This has been attributed to the
different methodology employed. For instance, the
function of central alpha-1 adrenoceptors is increased
in behavioural and electrophysiological studies in
animals. However, using radioligand binding
techniques, the number of alpha-1 adrenoceptors in the
rat brain is either unaltered after chronic treatment
with amitriptyline (Peroutka ,et—al., 1980; Tank et_
al..., 1981) and desipramine (Bergstrom et al-, 1979b;
Peroutka et al_., 1980); MA0I such as pargyline
(Perouta et al., 1980) and ECT (Bergstrom et al.,
1979a; Kellar et al., 1981); or decrease after 21 days
of imipramine treatment (Vetulani et al.,1980a).
1. 7.lb)Changes in alpha-2 adrenoceptor:
From animal studies, various forms of chronic
antidedepressive treatments have resulted in the
decline of alpha-2 adrenoceptor in various regions of
the rat brain measured with radioligand binding
A
techniques. For instance, treatment with the
tricyclics decreased the density of the receptor in
the locus coeruleus (Sevennson et al., 1978 1979;
McMillen et al.. 1980). Chronic administration of
tricyclic antidepressants or monoamine oxidase
inhibitors has been reported to reduce the number of
alpha-2 adrenoceptors in the cerebral cortex (Vetulani
et al., 1980b; Smith 1981; Campbell et al., 1982). A
similar decrease is found after repeated
electroconvulsive therapy. However, the result of
these binding studies should be taken with great care
as there are great discrepancies with respect to the
density of alpha-2 adrenoceptors when they are
labelled with different radioligands.
With reference to electrophysiological studies,
the results are opposite in different regions of the
brain: with supersensitivity in the facial motor
nucleus and amygdala (Menkes et al., 1980; Wang et
al., 1980) but subsensitivity in the locus coeruleus
after chronic administration with either desipramine
or imipramine (Svennson Usdin, 1978, 1979).
Concerning behavioural studies, the results
confirm the presence of subsensitivity of alpha-2
adrenoceptors in the rat brain following chronicA
antidepressant treatment. For instance, the chronic
treatment of imipramine and desipramine antagonise the
ability of low doses of clonidine to evoke hypothermia
(Gorka et al.. 1981).
1. 8 )Down-regulation of beta-adrenoceptor and
NE-coupled adenylate cyclase system after chronic
antidepressive treatments:
In general, a down-regulation of central
beta-adrenoceptor is commonly associated with
established forms of antidepressive treatments after a
therapeutically effective time basis. The brain region
exhibiting such effect include: cerebral cortex,
limbic forebrain, hippocampus (Bergstrom et—ad., 1979)
and pineal gland but not the striatum. Antidepressants
which show a down-regulatory effect include: a)the
tricyclics such as desipramine, imiprarnine,
amitriptyline, nortriptyline and chlorimipramine;
b)the MAOI such as pargyline, clorgyline, phenelzine
and tranylcypromine. In addition, repeated ECT
produces a similar effect (Bergstrom et al..1979:
Gillespie et al., 1979; Deaken et al., 1981; Sugrue,
1982). Thus, it is believed that the down-regulation
of beta-adrenoceptors may be related to the
therapeutic effects of antidepressive treatments.
Moreover, this down-regulation is rather specific to
antidepressants as chronic treatment with other
psychotropic drugs do not produce such effect
(Selliriger-Barnette et al., 1980). Consequently, the
parameter of down-regulation of beta-adrenoceptor is
currently being used as one of the indicators in
screening for potential antidepressants.
Usually, in the down-regulatory process, the
following 2 events occur together: l)a decrease in the
number, but not the affinity, of beta-adrenoceptor as
measured by radioligand binding (Banerjee et—aJL.,
1977; Bergstrom et al., 1979b; Clements-Jewery, 1978;
Gillespie et al., 1979; Sarai et al., 1978, Wolfe et
al., 1979), and the beta-1 subtype appears to be more
susceptible (Minneman et al., 1979a,b),
2)an decrease in the activity of the NE-stimulated
adenylate cyclase (Sulser, 1978).
On the other hand, the effects of chronic
administration of atypical antidepressants on the rat
brain beta-adrenceptor binding do not present such a
uniform picture. With respect to the binding data,
iprindole decreases but mianserin and zimelidine
either decrease or not alter, while nisoxetine does
not change the number of the binding sites. With
respect to the NE-stimulated adenylate cyclase,
A
however, all 4 atypical antidepressants reduce the
activityof the system (Clements-Jewetry, 1978; Mishra
et_al., 1980; Sellinger-Barnette et al.. 1980). Thus
the so called atypical or secondard generation
antidepressants are not atypical if one considers
their action on the beta-adrenoceptor-coupled
adenylate cyclase. The ability of chronic treatment
with antidepressants to decrease the NE-stimulated
adenylate cyclase activity without changing the
density of beta-adrenoceptor indicates that these 2
phenomena are not necessarily interdependent. Other
evidence which suggest that changes in
beta-adrenoceptor binding and adenylate cyclase may
not be coupled include the observation that incubation
of human astrocytoma or C-6 glioma cells with
isoproterenol results in a rapid loss in adenylate
cyclase activities before any change in beta-
adrenoceptor binding can be detected. (Su et al..
1979; Homburger et al.. 1980)
In contrast, another atypical antidepressant,
fluoxetine (a specific inhibitor of 5-HT uptake) has
been found to have no effect on either the density or
the affinity of beta-adrenoceptor (Mishra et al.,
1979; Maggi et al.. 1980). It also did not alter the
NE-stimulated adenylate cyclase activity (Mishra et
al., 1979).
In conclusion, it appears, that most if not all
antidepressants can down-regulate the NE-stimulated
adenylate cyclase with or without an effect on the
density of beta-adrenoceptor.
All of the experimental results described above
used rats as the animal model. A similar
down-regulation of the brain adrenergic system,
however, has also been found after chronic imipraroine
treatment in the cat (Briley et aJL., 1982). However,
the central beta-adrenoceptor in guinea—pigs has been
reported to remain unchanged after chronic
desipramine, pargyline and ECT treatment (Hu et—Qd.,
1980). A major limition in all of the experiments is
the use of 'normal' animals. The relationship of these
neurochemical changes to depressive illness in human
is unclear.
1.8.2Prerequisite conditions for the down-regulatior
of central beta-adrenoceptor:
1.8.2a)The esential role of norepinephrine:
Desenitization of the NE-coupled adenylate cyclase
and the beta-adrenoceptors after chronic
antidepressive treatments requires the unhindered A
occupancy of the adrenoceptor by NE.
The evidence in support of this view are as
follows: a)tricyclic antidepressants failed to
down-regulate the NE-coupled adenylate cyclase system
if presynaptic noradrenergic nerve endings have been
selectively destroyed by 6-hydroxydopamine or if the
beta-adrenoceptors were blocked by propranolol (Wolfe
et al., 1978; Schweitzer et_al., 1979); b)only the
(+)—oxaproti1ine (a potent NE uptake blocker) but not
the (—)—oxaproti1ine (a weak NE—uptake inhibitor) can
cause the subsensitivity of NE-1inked adenylate
cyclase and the reduction in the density of
beta-adrenoceptors (Mishra et aT., 1982a), c)only the
selective MAO-A inhibitor clorgyline but not the
selective MAO-B inhibitor deprenyl can increase the
level of NE and reduce the sensitivity of the
NE-sensitive adenylate cyclase as well as the density
of beta-adrenoceptor (Mishra et al.. 1982b); d)the
combination of an alpha-2 adrenoceptor antagonist with
either an NE uptake inhibitor or a MAO inhibitors
accelerates and intensifies the reduction in the
density of beta-adrenoceptors (Johnson et al., 1980);
e)desipramine fails to cause subsensitivity of
NE-sensitive adenyalte cyclase following lesions of
the locus coeruleus (Janowsky et al., 1982).
However, the availability of NE may only be one of
-v
the prerequisites for the desensitization process to
occur. This is indicated in the effects of unilateral
lesions of the locus coeruleus (a procedure that
depletes NE level) on the iprindole-induced
down—regulation of the beta-adrenergic system
(Janowsky et al., 1982). Iprindole which does not
affect the availabilty of NE fails to down-regulate
the system on the lesioned side, but can do so on the
non-lesioned side of the cerebral cortex. In addition,
cocaine which increases the availability of NE does
not alter the density of beta-adrenoceptors (Sethy et
al., 1981)
1. 9. 2, blRQle Ql serotonergic neuronal input in the
down-regulation process:
A requirement of serotonergic neuronal input for
the down-regulation of beta-adrenoceptor and the
NE-coupled adenylate cyclase may be implicated by the
following evidence: l)the terminal fields of
serotonergic projection in the rat cortex overlaps
with those of the noradrenergic projections; 2)result
of behavioural pharmacological studies have implicated
a relationship between the 2 neuronal systems;
3)several tricyclic antidepressants bound with high' A
affinity to serotonergic axons (Sette et al., 1981)
Recently, it has been shown that in the absence of
serotonergic neuronal input, desipramine reduce
neither the density of beta-adrenoceptors (Bruneilo et
al., 1982, Janowskv et al., 1982) nor the affinity of
the receptor for its antagonists (Janowsky et—al.,
1982) although the affinity to its agonist was
decreased (Manier et_al., 1982). However, the response
of the cAMP-generation system to stimulation by NE or
isoproterenol remains down-regulated as if the
serotonergic neurons were intact. These results
demonstrate that both serotonergic neuronal input and
NE are required for the regulation of the sensitivity
of the beta-adrenergic system to NE and isoproterenol
by desipramine of sensitivity.
In contrast, another group reported that after
the lesioning of serotonergic nerve terminals with
p-chloroamphetamine (PCA), both beta-adrenoceptor and
the adenylate cyclase can still be down-regulated by
chronic treatment with desipramine (Hall et al.,
1984).
1.9)The characteristics of rolipram:
Chemically, rolipram is a 4-[3-cyclopentyloxy—
4-methoxyphenyl]-2-pyrrolidone with an asymmetric
carbon atom in position 4 that vhas 2 possible
stereoisomers, in which the (-)-isomer is the active
form. Biochemically, it selectively inhibits
Ca2+-independent cAMP phosphodiesterase (Schwabe et
al., 1976; Wachtel 1982, 1983) but inhibits neither
monoamine oxidase nor the reuptake of NE, 5-HT or DA
into the presynaptic neuron (Watchel 1978, 1980).
1.9.1Antidepressant potentialities:
In animal models that screen antidepressants,
rolipram is suggestive of antidepressant actions
(Wachtel, 1982, 1983) as it a)antagonizes the
reserpine—induced hypothermia and hypokinesia, b)
potentiates the lethality of yohimbine in mice. Such
tests are designed to detect the enhancement o-f NE
availability within central synapses (van Riesen and
Delver, 1979; Slater £t al., 1979; Lapin, 1980).
However, the selectivity of the reserpine antagonism
test is questionable as drugs devoided of
antidepressive effects yield postive results, while
many of the newer antidepressants such as mianserin
and iprindole are screened as false negatives in the
test (MaJ 1979). Besides, no animal model can predict
the therapeutic usefulness of a presumptive
antidepressant, thus, the relevance of animal findingsA
will depend on the outcome of clinical trials.
The antidepressant potential has been
demonstrated in open phase II and a recent double
blind controlled clinical study (Zeller et al., 1984;
Wachtel, 1985 and Horowski et al., 1985). The open
clinical phase III studies has been conducted on
about 200 depressed patients (predominantly endogenous
or chronic depression, often resistant to conventional
drugs) at 20 separate and independent testing centres.
Rolipram is administered in increasing dosages up to 3
x 1.0 mgday. In about 23 of the cases, the
antidepressant properties is ranked as good to very
good. Moreover, the antidepressant action begins
within the first 12 hours to 10 days. Although the
trial yield encouraging results, only double-blind
trials can determine the true antidepressant efficacy
of rolipram.
1.9. 2)Effects of chronic rolipram treatment on
beta-adrenoceptor and the adrenoceptor coupled
adenylate cyclase in rat brain:
The findings in this area are scanty and
conflicting in spite of some similarities (Schultz
Schmidt 1985, 1986; Mork et al., 1983). Conflicting
results are found in the density of beta-adrenoceptor
and isoprenaline-stimulated cAMP generation. However,
the down-regulation of NE-stimulated cAMP production
is commonly reported.
With reference to beta-adrenoceptor, Schult et al
(1985, 1986) find that Bmax is decreased by 30% and
the Kd is unchanged as measured by 3H-DHA in membrane
preparation from cerebral cortex of rats treated with
racemic rolipram (10 mgkg once daily) for 9 days. In
contrast, both Bmax and Kd are unaltered in cerebral
cortex after treatment with rolipram (10 mgkg twice
daily) for 2 weeks in another investigation (Mork et
al., 1983).
Concerning the effect of chronic rolipram on
NE-stimulated (100 uM) cAMP production in cerebral
cortical slices, they are different in the magnitude
of down-regulation being 20% vs. 35% of the control
in Schmultz and Mork's group respectively. Such a
difference may be attributed to the duration of
treatment (9 days vs. 2 weeks) and the dosage of
rolipram used (10 mgkg once daily vs. twice daily).
The cAMP response to the specific beta-agonist
isoprenaline in cerebral cortical slices has' been
determined. Schultz and associates find that rolipram
treatment significantly diminishes
isoprenaline-stimulated cAMP formation by 27% after 9
days of treatment (Schultz et al., 1986). However,
Mork reports that the response is not significantly
different from the control (Mork et al.. 1983).
1.9.3)Effect of lesion of noradrenergic neurons on the
rolipram induced down-regulation of the adrenergic
cAMP generating system:
After the destruction of presynaptic
noradrenergic neurons by i.e.v. injection of 6-0HDA,
rolipram is administered at a dose of 1 mgdkg for 9
days. It is found that the denervation
supersensitivity elicited by 6—OHDA is alleviated by
subsequent rolipram treatment (Schultz et a1.. 1986).
To the knowledge of Schultz, this has never beer
observed with any other drugs.
In addition, rolipram treatment (1 mgdkg) for 9
days prior to and continuing after 6-OHDA injections
blunted the resulting receptor up-regulation
sigificantly (Schultz et al., 1986).
1.9. 4)The phosphodiesterase inhibitory effects of
rolipram:
The effect of rolipram on PDE activity is
characterized by 1)stereospecificity, 2)selectivity
3)differential inhibition and 4)regional specificity.
Such properties are illustrated in rat brain. For
instance, rolipram selectively inhibits cAMP PDE
activity while the cGMP degradation is unaffected
(Davis 1984). The inhibitory potency is limited to
calmodulin-independent isoenzyme (Davis, 1984) and is
especially potent on one of the three cAMP PDE
isolated by isoelectric fractionation. The inhibitory
effects of rolipram resides only in the (—)—enantiomer
(Schultz et al.. 1986; Schneider, 1986). The extent of
cAMP accumulation differ within brain areas, with
cortical structures being more responsive than
cerebellum (Schneider, 1984)
1. 9. 5)Stereospeoifioitv of rolipram action:
The potency of the isomers present is in the
order of (-)-isomer racemate (+)-isomer. For
instance: l)in the down-regulation of NE stimulated
cAMP production, the EC50 of (-)-isomer is about 50%
of the racemate, while the (+)-isomer does not show
any activity whatsoever (Schultz et al.,1987);
2)(-)-rolipram is about 15 times more potent-than the
(+)-isomer in animal tests that screen
antidepressants, this includes, a)the reversal of
reserpine induced hypothermia and hypokinesia; b)the
ability to cause head twitches, and c)the potentiation
of yohimbine lethality (Wachtel 1979, 1982, 1983).
1.9.6)Other charactistics of rolipram:
The dose-response relationship of rolipram in
human and rat are different. Its therapeutic
antidepressant activity in humans is found to be 0.025
to 0.2 mgkg (Horowski et al., 1985). In rats, maximal
down—regulation of NE—stimulated cAMP formation is
reported to be 1 mgdkg after 9 days of treatment.
The estimated ED50 is 0.35 mgkg.
The metabolic half-life in rats after oral
administration is about 1.5 hours (Wachtel 1979),
thus, it is unlikely that rolipram will interfere with
the in vitro radioligand binding studies if the
washout period is over 12 hours.
Rolipram does not directly interact with




2. 1)Animals and drug treatment:
Male Sprague-Dawley rats were bred and grew in the
animal house of the Chinese University of Hong Kong
until 5-6 weeks old. Then, they were transported to
the animal house in the Prince of Wales Hospital.
Drinking solution and pellet diet (Formerly Laboratory
Chow 5001C, Deans's Animal Feeds) were given ad
libitum. They were kept in rooms with a light-dark
cycle of 12 hour time interval.
5-6 weeks old male rats weighing initially 130-150A
g were injected intraperitoneally once daily for 11 or
17 days with rolipram (10 mgkg) ordesipramine (10
mgkg) in the experimental groups. Control animals
received the vehicle (10% Cremophor or 5% Tween 80
in saline) in a similar regiment.
Animals were killed by a sharp blow to the head
followed by cervical dislocation 17-24 hours after the
last injection. Whole brains and submandibular glands
were rapidly removed and kept frozen at —20 C until
the time for radioligand binding assays. The
activity of adenylate cyclase was assayed using
freshly prepared tissue homogenates.
2.2)Radioligand binding analysis:
The association of specific ligands for their
receptors can be studied quantitatively using
radioligand binding techniques. The technique
generally involves the use of radioactive isotope
labelled agonists or antagonists which can bind to
receptors with high affinity.
The binding of a radiolabelled ligand to its
receptor is saturable and reversible. Kinetically, the
binding reaction obeys the Law of Mass Action and will
attain an equilibrium after a suitable period of
incubation. At equilibrium, the receptor-boundw
radiolabelled ligand can be separated from the unbound
radiolabelled ligand by rapid filtration of the
reaction mixture through a glass microfibre filter.
The membrane-bound radiolabelled ligand trapped on the
filter can be measured radiometrically (Bennett,
1978).
2. 2. a)Preparation of cerebral cortex membranes:
The frozen brains were thawed. Cerebral cortical
tissues were then rapidly removed and weighed. All
subsequent manipulations were carried out at 4 C. The
tissues were homogenized in 10 vol (wv) of ice—cold
buffer B (50 mM Tris-HCl, pH 7.4 at 25°C) using a
Brinkman polytron PT-10 (setting 6, 10-15 s). This
homogenate was centrifuged at 45,000 x g for 10 mir
and the pellet was resuspended in 20 vol of buffer B.
The washing procedure was repeated twice. The pellet
was then resuspended in 50 vol of ice-cold buffer B
for the radioligand binding assays. 400 ul of the
membrane suspension was used for protein
determination.
2.2.b)Preparation of submandibular gland membranes:
The thawed submandibular glands were rapidly
separated from the adjoining connective tissues. They
were then weighed and immersed in 5 ml of KC1 buffer
solution (300 mM KC1 in 50 mM Tris-HCl, pH 7.4 at 25
°C) for 30 min. All manipulations were carried out at 4
°C. Subsequently, the glands were homogenized in the
KC1 buffer solution. The centrifugation and washing
procedures following the homogenization were similar
to that described for the cerebral cortex except that
the pellet was finally resuspended in 40 vol of buffer
B for the radioligand binding assay. 400 ul of the
membrane suspension was used for protein
determination.
2, 2, 0)Binding Of r3HlWB 4101 binding t-Q alphft-1
adrenoceptor:
Binding assay was performed as described by
U'Prichard et al. (1977). Binding assay was initiated
by adding 400 ul of cerebral cortex or submandibular
£land memhranfi DrfiDArfltinn in Hnnl i nfttft tn ?i vft«
final volume of 500 ul containing 50 mM Tris-HCl, pH
7.4 and 1 nM [3H]WB 4101. After 20 min incubation at
25°C, the binding reaction was terminated by rapid
filtration through glass fibre filters (Whatman GFB)
under suction. The filters were washed with 4 x 3 ml
of ice-cold buffer B. Radioactivity retained on the
filters was determined by liquid scintillation
spectrometry. Non-specific binding was defined as the
binding in the presence of 100 uM (-)-NE. Specific
binding was calculated by subtracting the non-specific
binding from the total binding.
2. 2. d)Binding of fSHIPAC to alpha-2 adrenoceptor:
Binding assay was performed as described by Rouot
Snyder (1979). The method was similar to that
described in section 2.2.c, except that 1 nM of
[3H]PAC was used and the incubation time was extended
to 30 min.
2« 2, e)Binding of T3H1DHA to beta-adrenooentor:
Binding assay was performed as described by Bylund
and Snyder (1976) as modified by Williams et al.
(1976). The procedure was similar to that described in
2.2.d., except the followings: 1)Several
concentrations (0.5-7 nM) of [3H]DHA, a
beta-adrenoceptor antagonist, were used,
2)non-specific binding was defined by 100 uM
(-)isoproterenol bitartrate, 3)the incubation was
performed at 37°C for 30 min.
2.2.f)Effect of rolipram on the binding of T3H1WB
4101. T3H1PAC and T3H1DHA tin vitro:%
6-7 weeks old Sprague-Dawley rats that had not
been treated with drugs were used. The membrane
homogenate of cerebral cortex and submandibular gland
were prepared as in sections 2.2. a and b. For each
receptor assay, the assay procedure was similar to
that described in sections 2.2 c, d and e. In the
absence of rolipram. However, in the experimental
group, 100 uM rolipram and 0.5% absolute ethanol were
included; in the control group, 0.5% of absolute
ethanol was added in the incubation medium. A list of



















2. 2.g)Scatchard analysis of the binding data:
Radioligand binding to a single population of
non-interacting site usually followsvkinetics similar
to those of classic enzyme-substrate interaction and
obeys the Law of Mass Action. For a reversible
ligand-receptor interaction:
(L) (R) (RL)
Where (R) concentration of unoccupied receptor
sites
(L) concentration of free ligand






As there is only a finite number of specific
binding sites per unit tissue, the ligand-receptor
interaction is saturable. The maximum number of









let (RL)= bound ligand =B









According to the Scatchard equation, if BF is
plotted vs B, a straight line can be obtained which
allows the determination of both the dissociation
constant (Kd= —1slope) and the number of binding
sites (Bmax= x-intercept).
2,3)Adenylate cvolase assay:
The adenylate cyclase activity was assayed by
following the production of cAMP from ATP as described
previously (Clement-Cormier et al., 1974) with minor
modifications. The cAMP formed was measured by the
protein binding method of Brown et al. (1972).
2. 3.a)Preparation of cerebral cortex homogenate:
After the appropriate drug treatment as indicated
in section 2.2, the rats were decapitated and the




After weighing, the frontal cortices were
immediately homogenized in 25 vol (vw) of buffer A (2
mM Tris-(hydroxymethyl) aminomethane-maleate buffer,
pH 7.4; 2 mM EGTA) with a glass homogenizer by 15
vertical strokes. All operations were performed at 4
°C.
The homogenate was assayed for adenylate cyclase
activity within 30 min of preparation.
2.3.b)Stimulation of cAMP accumulation:
The assay medium (final vol 0.5 ml) contained in
final concentrations: 80.2 mM Tris-(hydroxymethyl)
aminome t han e -me 1 e at e, PH7.4; 1 mM ATP; 4 mM MgS04; 10
mM theophylline; 50 ul of the enzyme preparation and
100 uM NE or 10 uM isoproterenol.
Crude preparations of adenylate cyclase are
usually contaminated with cAMP PDEs and ATPase. The
assay system therefore, included theophylline to
inhibit PDEs activity. Since less than 10% of the ATP
was hydrolysed under the experimental condition, an
ATP regenerating system was therefore not included
(Clement-Cormier et al.. 1975).
50 ul of the homogenates was first,incubated at 37
°C for 2 min with all the components of the assay
mixture except ATP. Reaction was initiated by the
addition of 50 ul of freshly prepared ATP and
continued for 3 min at 37 °C. As cAMP is heat stable,
the reaction was terminated by putting the assay tubes
in a boiling water bath for 3-5 min. The denatured
proteins in the reaction mixtures were sedimented by
centrifugation at 3,000 x g for 10 min. Then, the
tubes were stored at —20 C until they were assayed for
cAMP content within 2-3 days. Assays with boiled
tissue were used as controls (blanks). The difference
between the cAMP level in the experimental (native
enzyme) group and that in the control (boiled enzyme)
group gave an estimate of the amount of oAMP formed,
Under the experimental conditions used, adenylate
cyclase activity was proportional to time and enzyme
concentration.
2.3.c)cAMP determination:
For the determination of cAMP, the samples were
thawed and centrifuged at 3,000 x g for 10 min. cAMP
content in 50 ul aliquots of the supernatant was
measured by the saturation assay for cAMP developed by
Brown et al. (1972) using cAMP binding protein
prepared from calf adrenal glands.
In principle, the assay is based on the
competition between unlabelled cAMP and a fixed
quantity of [3H]cAMP for binding to an adrenal cAMP
binding protein. As the cAMP level in the samples
increases, the amount of [3H]cAMP bound to the binding
protein decreases proportionally. Thus, measurement of
the protein-bound radioactivity enables the amount of
unlabel led cAMP in the sample to be determined by
comparing with a standard curve performed in parallel.
Unbound cAMP was removed by adsorption onto charcoal
leaving protein bound cAMP in the solution.
The binding of cAMP to the binding protein may be
subjected to i nter-f erence by l)the two naturally
occurring nucleotides, ATP and cGMP (Albano e£ al.,
1974; Brown et al., 1972); and 2)divalent ions such as
Mg2+ and Ca2+ (Tovey et al. ,1974). However, ATP did
not interfere at concentration as high as 5 mM (Tovey
et al., 1974). In addition, the normal mammalian
tissue level of cGMP is unlikely to cause any
interference, since the cross-reactivity of cGMP is
200 times lower than cAMP towards the cAMP binding
protein (Tovey et al., 1974); but in mammalian
tissues, the concentration of cAMP is generally about
100 times higher than that of cGMP (Steiner et al.,
1972). The reduction of binding by divalent ions
(Tovey et al., 1974) was prevented by the inclusion of
4 mM EDTA in the assay buffer.
2.3.c.1)Preparation of cAMP binding protein:
The binding protein was prepared as described by
Brown et al. (1972). Briefly, bovine adrenal glands
were freshly collected from a slaughter house and kept
on ice. After the clearance of fats, the adrenal
cortex was separated from the medulla. The medulla was
homogenized with 1.5 vol of a medium containing 0.25 M
sucrose; 25 mM KC1; 5 mM MgC12 and 50 mM Tris-HCl, pH
7.4 at room temperature. The homogenate was
centrifuged at 10,000 x g for 5 min. The supernatant
was recentrifuged again at 10,000 x g for 15 min, The
supernatant was divided into 500 ul portions and
stored at -20°C. For cAMP determination, the binding
protein was thawed and diluted 20 fold with the assay
buffer to give a total binding of about 6,000 CPM at a
final [3H]cAMP concentration of 4.5 nM.
2.3.c.2)Preparation of charcoal solution:
Activated charcoal (neutral, Sigma) was stirred in
the assay buffer (50 mM Tris-HCl, pH 7.4; 4 mM
Na2EDTA) containing 2% BSA to give a charcoal
A
concentration of 75 mgml. The solution should be
prepared at least 15 min before the experiment.s
v
2.3.c.3)Preparation of other reagents:
[3H]cAMP (specific activity: 23.6 Cimmole,
Amersham) was freshly diluted with assay buffer to
give a 18 nM solution.
Stock cAMP solution (16 pmol50 ul) was diluted
serially with assay buffer to give the following
concentrations: 1, 2, 4, 8 pmole50 ul.
2, 3. G. 4) Assay protocol:
The following aliquots (ul) in duplicate wer
added to 1.5 ml plastic microcentrifuge tubes:
















50 ul of the working 3H-cAMP solution (18 nM) was
added to each tube. 100 ul of the cAMP binding protein
was added to all the tubes except the blanks. After
mixing, the tubes were kept at 0-4 C. After about 2
hours of incubation, 100 ul of a well-stirred ice-cold
charcoal suspension was added to each tube, mixed, and
centrifuged within 1.5 min at 10,000 x g at 4 C for 3
min. After centrifugation, 200 ul of the supernatant
was pipetted out for the determination of
radioactivity by liquid scintillation counting in a
home-made scintillation fluid (0.4 g P0P0P, 4 g PP0 in
1 litre mixture of 666 ml toluene and 333 ml Triton
X-100).
2.3.c.5)Data analysis:
Specific binding of [3H]cAMP was calculated by
subtracting the values of blank. The specific binding
in the absence of unlabel led cAMP (standard 0) was
designated as Co, while the specific binding in the
presence of unlabelled cAMP from standard or sample
was designated as Cx. The ratio of CoCx was
calculated for each tube. A linear calibration curve
was obtained by plotting CoCx against the amount of
A
cAMP in pmole50 ul from the standards. The amount of
cAMP in each sample can be read off from the standard
curve using the respective CoCx value.
2.4)Protein determination:
Protein content was determined as described by
Lowry et al. (1951) with bovine serum albumin
(Fraction 5, Sigma) as the protein standard.
2.5)Statistical analysis:
Data are expressed as the mean± S.E.M. The
student's t-test was used to evaluate the differences
between two means for statistical significance. The
criterion for significance was P 0.05.
The best-fit lines to the data points in Scatchard
analysis was determined by least-square linear
regression analysis.
2.6)Drugs:
Desipramine hydrochloride and rolipram are
generously donated by Ciba-Geigy Pharmaceuticals and
Sobering AG respectively. (-)-NE hydrochloride,
(-)-isoproterenol bitartrate, theophylline and ATP
were from Sigma, St. Louis. The radioactive compounds,
[3H]WB 4101 (specific activity, 27 Cimmol) and
[3H]DHA (specific activity 38 Cimmol) were from




3, 1) E-f-f ect o-f rolipram on the binding o-f
specific radioligands to central adrenoceptors:
Rolipram racemate (100 uM) in vitro did not affect
the specific binding of [3H]DHA (a selective
beta-adrenergic antagonist) and [3H]PAC (a selective
alpha-2 adrenergic partial agonist) to their
respective binding sites in the cerebral cortex (table
3.1). The result on beta-adrenoceptor is in agreement
with a previous finding by Schultz (1986) using 10 uM
rolipram racemate. Although rolipram decreased
significantly the specific binding of [3H]WB 4101 (an
A
alpha-1 adrenergic antagonist), the extent of change
was small( 10%, as shown in table 1J.
Table 3. 1
Effect of rolipram on
the binding of
specific radioligands to















Each value represents the mean+ S.E. of (n)Nseparate determinations
where n is the number of animals used. The unit for the results is
fmolmg membrane protein.
The cerebral cortex homogenate was freshly prepared as described.
The assay procedures were similar to that in the absence of rolipram
using 1 nM conc. of the respective radioligands. 100 uM rolipram and
0.5% ethanol was included in the experimental group, while only 0.5
% ethanol was included in the control.
The binding of [3H]WB4101 was significantly decreased by rolipram
with a p-value 0.05. (student's t-test, 2-tailed).
3,2)Effect of chronic rolipram or desipramine
treatment on beta-adrenoceptor in rat brain:
The specific binding of [3H]DHA (1 nM) to
beta-adrenoceptor in the cerebral cortex was
significantly decreased (30%) after desipramine
treatment for 11 (figure 3.1) and 17 days (figure
3.2). However, the specific binding of [3H]DHA (i nM)
in the rolipram treated group was not significantly
different from the controls both after 11 (figure 3.1)
and 17 days (figure 3.2) of drug treatment. To
determine whether the drug treatments altered the
number of binding sites or the affinity of the binding
sites for the radioligand, tissue samples were
incubated with various concentration (0.5 to 8 nM) of
[3H]DHA. The data were then analysed by the method of
Scatchard (1949).
The binding of various concentration of [3H]DHA to
the rat cerebral cortex homogenate was monophasic and
saturable (figure 3.3 and 3.4). This is consistent
with the notion that [3H]DHA binds to a single
population of beta-adrenoceptor with a finite number
of binding sites.
Scatehard analysis of [3H]BHA binding to the
cerebral cortex homogenate from rats chronically
treated with rolipram (10 mgkg, i.p., once daily)
revealed no significantly alteration of the binding
characteristics (Bmax and Kd values) of the
radioligand both after 11 (figure 3.3 and table 3.2)
and 17 days (figure 3.4 and table 3.3) of treatment.
In contrast, Scatehard analysis showed that
desipramine treatment (10 mgkg, i.p., once daily) was
associated with a significant decrease (25 to 36%) of
»
the maximum number of beta-adrenoceptors (Bmax value)
both after 11 (figure 3.3) and 17 days (figure 3.4) of
v.
drug treatment. However, this loss of
beta-adrenoceptors was not accompanied with any change
in the apparent affinity of the receptor for 3H-DHA
(Kd value) as shown in table 3.2 and table 3.3
respectively.
control rolipram desipramine
Figure 3.1: Effect of 11 days treatment with rolipram and
desipramine on the beta-adrenoceptors in the rat cerebral
cortex.
Results were expressed as the means± S.E. The specific
binding of 3H-DHA (1 nM) after 30 min incubation at 37°C in
the control, rolipram and desipramine treated groups (n=5)
were 48.12± 1.4, 47.5± 1.6 and 34.72± 1.7 respectively.
The desipramine-treated group was significantly different
from the control with a p-value 0.05 (student's t-test,
2-tailed)
control rolipram desipramine
Figure 3.2: Effect of 17 days treatment of
rolipram and desipramine on the
beta-adrenoceptors in rat cerebral cortex.
Results were expressed as the means± S.E.
Rolipram (10 mgkg), desipramine (10 mgkg) and
vehicle (5% Tween 80 in saline) were administered
to rats. The specific binding of 3H-DHA (IhM)
after 30 min incubation at 37°C in the control,
rolipram and desipramine treated groups were
59.98± 0.32 (n=6), 58.50± 1.0 (n=7) and 44.72±
3.8 (n=6) respectively. The specific binding in
the desipramine treated group was significantly
different from the control with a p-value 0.05
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Figure 3.3: Effect of 11 days treatment of rolipram and desipramine
upon the specific binding of 3H-DHA to cerebral cortical membranes of
rats.
Large graph: showed the saturation curves. The ordinate represented
the amount of 3H-DHA specifically bound; the abscissa represented the
concentration of 3H-DHA in the incubation medium. Each values was
expressed as the group mean.
Inset graph: showed the Scatchard plots of the same data. The ordinate
represented the ratio of 3H-DHA specifically bound to those free in the
incubation medium; the abscissa represented the amount of 3H-DHA
specifically bound. For each of the Scatchard plot, the best fit
regression line was shown with the x-intercept and -1slope representing
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Figure 3.4: Effect of 17 days treatment of rolipram and desipramine
upon the specific binding of 3H-DHA to cerebral cortical membrance of
rats.
Large graph: showed the saturation curves. The ordinate
represented the amount of 3H-DHA specifically bound; the abscissa
represented the concentration of 3H-DHA in the incubation medium.
Each value was expressed as the group mean± S.E.
Inset graph: showed the Scatchard plots of the same data. The
ordinate represented the ratio of 3H-DHA specifically bound to those
free in the incubation medium; the abscissa represented the amount of
3H-DHA specifically bound. For each of the Scatchard plot, the best
fit regression line was shown with the x-intercept and -1slope
representing the values of B max and Kd respectively.
Table 3. 2
Scatchard analysis of
the effect of 11 days of
rolipram and desipramine treatment on
beta-adrenoceptor
















Each value is the mean± S.E. The number in parentheses
indicates the number of rats in each group.
Rolipram or desipramine (10 mgkg, i.p., once daily) was
administered to male rats weighing initially 150-170 g for 11
days; the controls received the vehicle (10% Cremophor EL in
saline). The rats were killed 17-24 hours after the last
injection. The beta-adrenoceptors in the cerebral cortex
homogenates were assayed after 1 day of storage at —20 C. The
central beta-adrenoceptors after desipramine treatment (the
value marked by asterisk) was significantly different from the
control with a p-value 0.05 (student's t—test, 2-tailed)
Table 3.3
Scatchard analysis of
the effect of 17 days treatment of
desipramine and rolipram to
beta-adrenoceptor in















Each value is the mean± S.E. The number in parentheses
indicates the number of rats in each group. v
Rolipram or desipramine (each of 10 mgkg, i.p., once daily) was
administered to male rats weighing initially 130-150 g for 17
days. The rats were killed 17-24 hours after the last injection.
The beta-arenoceptors in the cerebral cortex homogenates were
assayed with 0. 5- 8 nM of [3H]DHA after 24 hours of storage at
-20°C. The Bmax value was significantly decreased by desipramine
treatment (marked by asterisk) as compared to the control with a
p-value 0.05 (student's t-test, 2-tailed).
3, 3)Effeot Ql chronic; rolipram or desipramine
treatment on adenylate cyclase activity in rat brain:
In the present study, the basal and the
adrenoceptor stimulated activities of adenylate
cyclase were assayed on cell-free crude membrane
homogenates of rat frontal cortex. Thus, the
beta-adrenoceptor and the receptor-linked adenylate
cyclase were both performed on membrane homogenates.
When compared with the respective control groups,
the basal activities of adenylate cyclase were not
altered by racemic rolipram both after 11 and 17 days
of treatment (table 3.4 and 3.5). Thex basal adenylate
cyclase activity was also not changed after 17 days of
desipramine treament (table 3.5).
To determine if there was any difference in the
adrenoceptor stimulated activities of adenylate
cyclase between the drug treated groups and the
controls, a maximal effective dose (100 uM) of (-)-NE
(Schultz et al,, 1986) was tested. With chronic
desipramine (10 mgkg, i.p., once daily) treatment, a
significant decrease (approx. 30%) in the adenylate
cyclase responsiveness to 100 uM NE was observed after
17 days of drug treatment (table 3.5). In contrast,
the net stimulated adenylate cyclase activities
were not significantly different from the controls
after chronic rolipram treatment for 11 (table 3.4)
and 17 days (table 3.5). The net stimulated adenylate
cyclase activities refer to the amount of cAMP
produced in the presence of NE (100 uM) minus that of
the basal activities.
As NE is a non-specific adrenoceptor agonist, it
may stimulate cAMP formation in the rat cerebral
cortex via both alpha- and beta-adrenoceptors (Schults
and Daly, 1973; Perkins nad Moore, 1973). Thus, in
order to determine the effects of drug treatments on
the beta-adrenoceptor, the cAMP'v response to
(-)-isoproterenol (a specific beta-agonist) was
determined. Again a maximal effective concentration of
isoproterenol (10-30 uM) was used.
The net stimulation of the adenylate cyclase
activity to 10 uM (-)-isoproterenol was not
significantly different between the rolipram and the
control groups after 11 (table 3.4) and 17 days (table
3.5) of rolipram treatment. In contrast, desipramine
significantly decreased the net stimulation by about
50% as compared to the controls after 17 days of
treatment (table 3.5)
Table 3.4
Effect of 11 days treatment of
rolipram on
adenylate cyclase activity in
rat frontal cortex homogenate
Adenylate cyclase activitiesTreatment n
basal net NE (100 uM) net isoproterenol











The adenylate cyclase activity is expressed in pmol cAMPmg membrane
protein-min.
Each value is expressed as the mean± S.E. of (n) separate animals.
The activity of adenylate cycalse was assayed fresh (30 min after the
membrane preparation) in crude membrane homogenates of rat frontal
cortex 24 hours after the last drug injection.
The basal, net NE-stmulated and the net isoproterenol-stimulated
activities of adenylate cyclase in the rolipram group were not
significantly different from the controls (student's t—test, 2—tailed).
The net stimulated adenylate cyclase activities refer to the amount of
cAMP produced in the presence of agonists minus that of the basal
activities.
T ab1e 3.5
Effect of 17 days treatment of
desipramine and rolipram on
adenylate cyclase activity in
in rat frontal cortex homogenate
Treatment n adenylate cyclase activities
basal net NE (100 uM) net isoproterenol














18. 1± 2. 0
17.0±, 1.7
The adenylate cyclase activity is expressed- in pmol cAMPmg membrane
protein-min.
Each value is the mean+ S.E. of (n) separate animals.
The activity of adenylate cyclase was assayed fresh (30 min after the
membrane preparation) in crude membrane homogenates of rat frontal
cortex 24 hr after the last drug injection.
Both the basal, the net NE- and the net isoproterenol-stimulated
activities of adenylate cyclase in the rolipram group were not
significantly different from the control; while the net NE (100 uM) or
isoproterenol (10 uM) stimulation in the desipramine group were
significantly decreased as compared to the controls (student's t—test,
2-tailed). The net stimulated adenylate cyclase activities refer to
the amount of cAMP produced in the presence of agonists minus that of
the basal activities.
3. 4)Effeet of chronic rolipram or desipramine
treatment on alpha-adrenoceptor in the rat brain:
The rat cerebral cortex alpha-1 adrenoceptors
labelled with [3H]WB4101 were not altered after 11
(table 3.6) and 17 days'(table 3.7) treatment with
rolipram or desipramine.
Similarly, alpha-2 adrenoceptors labelled with
[3H]PAC, were not changed after chronic (11 and 17
days) treatment with rolipram (table 3.8 and table
3.9). However, there was a significant decrease in
the alpha-2 adrenoceptor after 17 days of desipramine
treatment (table 3.9) which was not observed if
desipramine was given for 11 days (table 3.8) only.
T ab1e 3.6
Effect of 11 days treatment of
desipramine or rolipram on
the alpha-1 adrenoceptor
in the rat cerebral cortex
Treatment n r3HIWB4101 specifically bound










Each value is the mean+ S.E. of (n) separate animals.
The assay for alpha-1 adrenoceptorsx was performed on
freshly prepared brain homogenates of rats killed 24
hours after the last injection of drug (10 mgkg, i.p.,
once daily each of rolipram or desipramine in the
experimental groups; the control received the vehicle-5
% Tween 80 in saline). The concentration of the
radioligand used was 1 nM, the non-specific binding was
determined in the presence of 100 uM (-)—NE. The amount
of [3H]WB4101 bound to the membranes of the drug-treated
groups was not significantly different from the controls
(student's t-test).
Table 3.7
Effect of 17 days treatment of
desinramine or rolipram
on the alpha-1 adrenoceptor in
the rat cerebral cortex











Each value is the mean± S.E.of (n) separate animals. The
assay was performed on tissue stored frozen at -203 for
2 months. The concentration of the radioligand used was 1
nM, non-specific binding was determined in the presence
of 100 uM (-)-NE. The values after drug treatment (10
mgkg, i.p., once daily each of rolipram and desipramine)
were not significantly different from the control (5%
Tween 80 in saline).
Table 3. 8
Effect of 11 days treatment of
desipramine or rolipram on
the alpha-2 adrenoceptor in
the rat cerebral cortex











Each value is the mean+ S.E. of (n) separate animals.
The assay was performed on freshly prepared cerebral
cortex homogenates. The concentration of the radioligand
used was 1 nM, the non-specific binding was determined in
the presence of 100 uM (-)-NE. The amount of specific
binding in the durg-treated groups (10 mgkg, i.p., once
daily each of rolipram and desipramine) were not
significantly different from the control (5% Tween 80 in
saline) as analysed by student's t-test.
Table 3.9
Effect of 17 days treatment of
desipramine or rolipram on
the alpha-2 adrenoceptor in
the rat cerebral cortex
Treatment n f3H!PAC specifically bound










Each value is the mean± S.E. of (n) separate animals.
The drug treated group received 10 mgkg, i.p., once
daily each of rolipram and desipramine; while the control
received 5% Tween 80 in saline. The brain had been
stored at -20 °C for 2 months before the assay. The
cerebral cortex homogenate was assayed for alpha-2
adrenoceptors by using 1 nM [3H]PAC, non-specific binding
was determined in the presence of 100 uM (-)-NE. The
amount of [3H]PAC specifically bound was significantly
decreased after chronic desipramine treatment with a
p-value 0.05 (student's 2-tailed t-test).
3, 5)Effect of rolipram on the binding of specific
radioligands to adrenoceptors of rat submandibular
glands:
Rolipram racemate (100 uM) did not affect the
binding of [3H]WB4101, [3H]PAC and [3H]DHA to the
alpha-1, alpha-2 and beta-adrenergic binding sites in
the rat submandibular glands (table 3.10). This result
was similar to that observed in the brain (table 3.1).
Table 3.10
Effect of rolipram on
the binding of specific radioligands to
adrenoceptors in the rat submandibular gland










Each value is the mean± S.E. of (n) separate determinations.
Specific binding was expressed as fmolmg membrane protein.
The number in parentheses indicated the number of rats used. The
binding assay was performed on freshly prepared cerebral cortex
homogenates 24 hrs after the last drug injections. Result showed that
100 uM rolipram had no effect on the binding of 1 nM each of the
specific radioligands to their respective binding sites. The
difference between the means was tested by student's t-test,
2-tailed.
3, 6)Effeot Of chronic treatment of rolipram or
desipramine on the beta-adrenoceptor in the rat
submandibular glands:
Similar to the central beta-adrenoceptors (figure
3.1 and 3.2), chronic rolipram treatment did not alter
the number of beta-adrenoceptors in the submandibular
gland after 11 and 17 days treatment (figure 3.5 and
3.6 respectively). On the contrary, desipramine
treatment was associated with a significant decrease
(approx. 30%) in the density of beta-adrenoceptors
(figure 3.5 and 3.6) after 11 and 17 days desipramine
treatment. The percentage of decrease was similar to
that observed in the cerebral cortex (table 3.2 and
3.3) after the same period of drug administration.
conetrol rolipram desipramin
Figure 3.5: Effect of 11 days treatment with rolipram and
desipramine on the beta-adrenoceptors in the rat
submandibular glands.
Results were expressed as the means± S.E. Desipramine (10
mgkg), rolipram (10 mgkg) and vehicle (5% Tween 80 in
saline) were administered to rats. The specific binding of
3H-DHA (1 nM) after 30 min incubation at 37 °C in the
control, rolipram and desipramine treated groups were:
50.90± 8.2 (n=6), 69.80± 12.0 (n=4) and 78.80± 9.3 (n=5)
respectively. The desipramine treated group was
significantly decreased as compared to the control with a
p~value T 0.05 (student's t-test, 2 tailed).
control
, • •
Figure 3.6: Effect of 17 days treatment with rolipram and
desipramine on the beta-adrenoceptor in rat submandibular
gland. Results were expressed as the means± S.E. The
specific binding of 3H-DHA (1 nM) after 30 min incubation at
37°C in the control, rolipram and desipramine-treated groups
were: 48.33± 1.9 (n=4), 47.29± 2.0 (n=6) and 37.90± 1.3
(n=4). The specific binding of 3H-DHA to the desipramine
treated group was significantly decreased as compared to the
control with a p-value 0.05 (student's t-test, 2-tailed).
Table 3. 11
Effect of 17 days treatment of
dfisiprflmine and rolipram on
beta-adrenoceptors
in the rat submandibular gland










Each value is the mean+ S.E. of (n) separate animals.
The submandibular glands had been stored at -20°C for 2
months before the assay. The value with asterisk was
siginificantly different from the control with a p-value
0.05 (student's t-test, 2-tailed). The concentration of
[3H]DHA used was 1 nM, non-specific binding was
determined by displacing the radioligand with 100 uM
(-)-isoprotenerol.
3.7) Effect; of chronic rolipram or desipramine
treatment on the alpha-adrenoceptors in the rat
submandibular gland:
The density of alpha-1 adrenoceptor in the rat
submandibular glands labelled with [3H]WB 4101 (1 nM)
was not altered after 11 days of desipramine or
rolipram treatment (table 3.12). After 17 days of drug
treatment, the number of alpha-1 adrenoceptor was
decreased (30-40%) in the rolipram treated group
(table 3.14) while no significant difference was
observed after desipramine treatment (table 3.13). In
A
contrast, the level of [3H]WB 4101 in the rat cerebral
cortex was not changed significantly after chronic
rolipram and desipramine treatment (table 3.6 and
3.7).
The density of alpha-2 adrenoceptor in the rat
submandibular gland labelled with [3H]PAC (1 nM) was
not changed after 11 days of desipramine and rolipram
treatment (table 3.14). A significant decrease
(approx. 20%) however, was observed in the cerebral
cortex after 17 days of desipramine treatment (table
3.9).
Table 3.12
Effect of 11 days treatment of
desipramine or rolipram on
alpha-1 adrenoceptor in
the rat submandibular gland











Each value is the mean± S.E.of (n) separate animals.
The submandibular glands were stored at -20°C for 24
hours before the assay. The concentration of the
radioligand used was 1 nM, the non-specific binding was
determined in the presence of 100 uM (-)-NE. The level of
alpha-1 adrenoceptor in the rolipram treated groups was
significantly different from the control with a p-value
0.05 (student's t-test, 2-tailed).
Table 3,13
Effect of 11 days treatment of
desipramine and rolipram on
alpha-2 adrenoceptors in
the rat submandibuar gland











Each value is the mean+ S.E of (n) separate animals. The
submandibular glands were stored at -20 °C for 1 day
before the assay. The concentration of [3HJPAC used was 1
nM; the non-specific binding was x determined in the
presence of 100 uM (—)-NE. The level of alpha-2
adrenoceptors in the drug-treated group was not signific
ntly different from the control (student's 2-tailed
t-test).
Table 3.14
Effect of 17 days treatment of
desipramine and rolipram on
alpha-1 adrenoceptors in
the rat submandibular gland











Each value is expressed as mean± S.E. of (n) separate
animals. The submandibular gland had been stored at -20
°C for 2 months before the assay. The concentration of
the radioligand used was 1 nM. The binding in the
rolipram treated group was significantly lower as




4.1) Effect o-f chronic rolipram treatment on the
den si t. y of beta-adrenoceptor and the NE- or
isoproterenol stimulated adenylate cyclase in the rat
brain:
The present study demonstrated that chronic (11
and 17 days) administration of racemic rolipram (10
mgkg, i.p., once daily) did not down-regulate the
number of beta-adrenoceptors (Table 3.2 and 3.3). Any
residual rolipram in the brain was unlikely to affect
the binding of [3H]DHA to the beta-adrenoceptors, as
l)the brain membrane had been washed 3 times before
the assay; 2)the metabolic half-life of rolipram in
rats is short, about 1.5 hr after oral administration
(Wachtel, 1979). It was therefore unlikely for
rolipram to accumulate to any appreciable extent in
the brain; 3)100 uM rolipram added in vitro to control
incubations did not alter [3H]DHA binding in the
cerebral cortex homogenates (table 3.1).
In contrast, the administration of desipramine (10
mgkg, i.p., once daily) decreased the number of
beta-adrenoceptors by about 30% without affecting
their Kd values both after 11 and 17 days of treatment
(table 3.2 and 3.3). This finding with desipramine is
in accordance with that of Banerjee et al. (1977 and
1979). They reported a 40% reduction of the number of
[3H]DHA binding sites after 6 weeks of desipramine
treatment.
Mork and co-workers (1983) treated rats with
rolipram (10 mgkg) twice daily for 2 weeks and used
[3H]DHA to study the beta-adrenoceptors in the
cerebral cortex. Similar to the present study, they
observed no significant difference in both the Bmax
and Kd of the [3H]DHA binding sites between the
control and the rolipram-treated group.
A wealth of experimental data indicates that a
persistent occupancy of the adrenoceptors by its
•V
agonist is one of the prerequisites for the
development of down-regulation of beta-adrenoceptor.
Although acute administration of rolipram has been
found to increase noradrenergic transmission by
enhancing the NE turnover (Watchtel 1978, 1980), its
relatively short biological half—life may not permit a
sustain increase in the synaptic levels of NE for a
sufficient period to down-regulate the
beta-adrenoceptors.
To test this fully, it may be necessary to
administer the short-acting rolipram in some sustained
mariner, eg., via an osmotic minipump. Alternatively,
this lack of effect of rolipram may not be the result
of inadequate dosage due to the short metabolic
half-life of the drug, as other clinically effective
long-acting antidepressants have been reported to be
inactive in this biochemical model. For instance,
trimipramine (Rifkin et al.,1980: Salzman, 1965) with
a metabolic half-life is 23± 1.9 hr, did not
down-regulate brain beta-adrenoceptors after 28 days
of treatment (30 mgkg, i.p., once daily) in the rat
(Hauser et al., 1985). Similarly, the number of
beta-adrenoceptors were not altered after 4 weeks
treatment of maprotiline and nomifensine (both are
long-acting NE uptake inhibitors and effective
antidepressants) which cannot be accounted for by
having short metabolic half-lives (Waldmeier et al.,
1976; Maitre et al., 1971; Kellner et al., 1977).
It is possible that an enhanced NE signal input
per se is not the only requirement for the
down-regulation of beta-adrenoceptors. This argument
can be further illustrated by the following
observations: l)iprindole which does not increase the
availability of NE can still cause a marked
down-regulation of beta-adrenoceptors (Janowsky et
al,, 1981; Wolfe et al., 1978); 2)continuous infusion
of the short—acting NE reuptake inhibitor, cocaine,
•fails to down-regulate the beta—adrenoceptor5 (Pander
and Davis, 1981a; Sethy and Harris, 1981).
On the other hand, Schults et al. (1986) found
that chronic treatment with rolipram racemate (10
mgkg, i.p., once daily) suspended in the 1% Tyrose
significantly decreased the Bmax value of [3H]DHA
binding sites by 30% while leaving the Kd value
unchanged. However, the results of Schults et al. was
based on the comparison between the rolipam and saline
treated groups, while the effect of the vehicle (1%
Tyrose) was not reported. In the present study, the
commonly used vehicle for rolipram eg. Cremophor EL
(10%) and Tween 80 (10%) was found to have different
extent of vehicle effects on different adrenoceptors.
It is therefore important to ascertain if 1% Tyrose
has any vehicle effects on the beta-adrenoceptors.
Chronic antidepressive treatments have generally
been reported to decrease the number of cortical
beta-adrenoceptors (Bannerjee et al., 1977).
Furthermore, the onset of the down-regulation is
correlated temporally with the clinical antidepressive
actions. For instance, repeated ECT has been shown to
have a faster onset of antidepressant action in man
and it also rapidly decreased the density o-f
beta-adrenoceptors after 8-12 days of treatment in
rats to a similar level as in chronic desipramine
treatment (Pandey et al., 1979). The results of an
open clinical phase 2 trials (Zeller et al.. 1984;
Wachtel, 1985; Horowski et al. 1985) suggest that
rolipram may be a potential antidepressant with an
early onset of therapeutic effects (first 10 hours to
10 days). If this is the case, one would expect to see
a down-regulation of the central cortical
beta-adrenoceptors as early as after 10 days of
rolipram treatment However, no significant change in
v
the beta-adrenoceptors was observed« after 11 to 17
days of rolipram treatment in the present study. This
finding, therefore, did not support the notion that
rolipram may exert an antidepressive effect by a
down-regulation of beta-adrenoceptors.
Bearing in mind that there are effective
antidepressants such as mianserin, nomifensine, the
tetracyclic maprotiline and the tricyclic trimipramine
which do not decrease the density of
beta-adrenoceptors (Garcha et al., 1985; Mishra et
al., 1980; Hauser et al., 1985), it would be premature
to rule out the usefulness of rolipram as an
antidepressant. Indeed, 2 other potential
antidepressants, nisoxetine and fluoxetine which are
currently under clinical trials also did not decrease
the number of beta-adrenoceptors upon chronic
treatment in the rat (Mishra et al.. 1979; Maggi et
al.. 1980).
Rolipram racemate (10 mgkg, i.p., once daily) not
only have no effect on the density of
beta-adrenoceptors (table 3.2 and 3.3) it also did not
alter the NE or isoproterenol-stimulated adenylate
cyclase activities in the rat cerebral cortex after 11
A
(table 3.6 and 3.7) and 17 days (table 3.8 and 3.9) of
treatment. Mork et al. (1983) found that chronic
rolipram (10 mgkg, i.p., twice daily) treatment did
not change the isoproterenol-stimulated cAMP
production but did lower the NE-stiraulated adenylate
cyclase activity in rat cerebral cortical slices.
Schultz et al. (1985) also found that chronic rolipram
racemate treatment (10 mgkg, i.p., once daily)
reduced both the NE- and isoproterenol-stimulated
adenylate cycalse activities in rat cerebral cortical
slices. In addition, Schultz et al. (1986) showed that
the affinity of the adrenoceptors (as meaured by
EC50) was unchanged from a dose reponse curve for NE
induced cAMP accumulation in cerebral cortical
slices.
Based on the parameter of down-regulation of
NE-stimulated adenylate cyclase, the present finding
suggests that rolipram may not be an antidepressant.
In contrast, the result from Mork et al.. (1983) and
Schultz et al. (1985) would suggest the opposite.
However, the use of the down-regulation of
beta-adrenoceptors and reduced responsiveness of
adenylate cyclase to NE and isoproterenol stimulation
as a biochemical index to screen potential
antidepressants may not be very satisfactory. Several
clinically effective antidepressants such as
nomifensine (Garcha et al., 1985), maprotiline (Garcha
et al., 1985), trimipramine (Hauser et al. 1985), and
fluoxetine were proved to be as effective as
imipramine clinically (Levine et al., 1987) and yet
failed to affect both the density of
beta-adrenoceptors and the NE-stimulated adenylate
cyclase. They would thus be regarded as
non-antidepressants on the basis of this screening
procedure. While the result with another established
antidepressant mianserin would be controversial as the
effect of mianserin on the beta-adrenergic system
depends on the dosage used: 10 rugkg i.p. administered
for 28 days showed negative results (Mishra et—al.,
1980) while 30 rngkg treated in the similar regime
produced a 37% reduction in the response of adenylate
cyclase but the density of beta-adrenoceptor remained
unaltered (Mishra et al.. 1980).
In conclusion, although the down-regulation of
beta-adrenoceptors has been postulated as a common
mode of mechanism of antidepressive treatments, there
are evidences which challenge this hypothesis in
addition to the above mentioned antidepressants that
do not seem to affect the beta-adrenoceptors and the
NE-1inked adenylate cyclase. For instance, the
down-regulation of beta-adrenoceptors can also be
induced by thyroidectomy (Gross et al. 1980), stress
(Stone Piatt, 1982), amygdala kindling (McNamara,
1978) and estrogen treatment (Wagner Davis, 1980)
and yet these procedures are without antidepressive
effects.
4.2)Effect of chronic desipramine administration on
beta-adrenoceptors in the rat submandibular glands:
While chronic antidepressive treatments generally
down-regulates beta-adrenoceptor in the CNS (Vetulani
et al. 1976; Sugrue, 1982; Wolfe et al. 1978), there
is little information concerning the effect of such
treatment on the peripheral adrenoceptors. The present
study was also undertaken to determine if peripheral
adrenoceptors in rat submandibular glands were
regulated by antidepressants in a manner similar to
that described in the CNS.
There is evidence to suggest that the peripherial
beta-adrenoceptors may be more resistant to the
regulatory effect of antidepressants. For instance,
Keith et al. (1986) found that the administration of
20 mgkg of imipramine twice daily for 4 days had no
significant effect on peripherial beta-1 adrenoceptor
sensitivity in the isolated right atria of rat. The
A
same treatment, however, decreased the number of
central beta-adrenoceptors by 30 to 40%. Moreover,
Crews and Smith (1978) reported that the sensitivity
of peripheral beta-1 adrenoceptors of the left atria
of rats were unchanged after 3 weeks of desipramine
treatment (10 mgkg, twice daily). In the present
study, chronic desipramine treatment (10 mgkg, i.p.,
once daily) was able to decrease the binding of
[3H]DHA to beta-adrenoceptors in the submandibular
gland (figure 3.5 and 3.6). The extent of decrease
(about 30%) was similar to that observed in the
cerebral cortex (table 3.2 and 3.3) after the same
period of desipramine treatment. Although the precise
subtype of beta-adrenoceptor being down-regulated in
the present study had not been
determined, it is presumably the beta—1 adrenoceptors,
as beta-1 adrenoceptors are the subtype that responded
to the drug treatment (Arnett et al. 1979). Thus, the
present result indicates that the beta-adrenocptors
in the rat submandibular gland are not more resistant
to the modulatory effects of desipramine after 11 and
17 days of treatment. Whether there is a differential
response between the submandibular gland and the brain
to desipramine treatment at earlier time points
remains to be determined. However, the lack of effect
of chronic antidepressant treatment on
A.
beta-adrenoceptors in the heart may show that this
regulatory action of desipramine is tissue specific.
In the cerebral cortex, the down-regulation of
beta-adrenoceptors has been shown to be dependent upon
the presence of intact presynaptic noradrenergic
(Schweitzer et al. 1979; Wolfe et al. 1978) and
serotonergic neurons (Bruneilo et al., 1982; Janowsky
et al., 1982). In spite of a dense innervation by
adrenergic neurons, the submandibular glands appear
not to be innervated by sertonergic neurons, and yet
the beta-1 adrenoceptors are down-regulated upon
chronic desipramine treatment. This may imply either
the salivary gland beta-adrenoceptors are regulated in
a different manner from the central ones, or the
requirement for intact presynaptic serotonergic
neurons in the down-regulation of central
beta-adrenoceptor is not absolute.
Indeed, the necessity of the presence of an intact
5-HT system for the down-regulation of central
beta-adrenoceptor remains debatable. Sulser (1986)
summarised the supporting evidence as follows:
l)Long-term treatment with desipramine did not
decrease the number of beta-adrenoceptors if. the
serotonergic system was destroyed by
5,7-dihydroxytryptamine injections vin the raphe
nucleus (Bruneilo et al. ,1982; Janowsky et al.,
1982), or if the synthesis of 5-HT was inhibited by
p-chlorophenylanine; 2)The therapeutic activity of
antidepressants can be nullified by
p-chlorophenylanine which inhibits the synthesis of
5-HT; 3)In animal experiments, desipramine-resistant
beta-adrenoceptors can be converted to
desipramine-responsive beta-adrenoceptors by the
coadministration of 5-HT. This is also supported
clinically as 5-HT has been reported to enhance the
therapeutic activity of MAOI and tricyclic
antidepressants.
Con-flicting data on the requirement of an intact
serotonergic system for the down-regulation of
beta-adrenoceptors by chronic antidepressive
treatments include: l)The ability of desipramine to
decrease the number of beta-adrenoceptors in rats was
not impaired after effective depletion of cortical
5-HT with PCPA and PCA treatment (Nimgaonkar et al..
1985; Hall et al., 1984); 2)Repeated electroconvulsive
shock treatment also decreased the density of the
receptor in PCPA-treated rats; 3)The modulation of
cortical beta-adrenoceptor by chronic mianserin or
A
iprindole treatment can still occur in rats treated
with 5,7-DHT, a selective chemotoxin of serotonergic
neurons (Gandolfi et al., 1984). However, in the same
study, the attenuation of beta-adrenoceptor by chronic
imipramine treatment was abolished.
4.3 differences in the beta-adrenocptor stimulated
adenylate cyclase activity in cell-free homogenates
and brain slices:
In the present study, the assay of
beta-adrenoceptor using radioligand ligand binding
technique and adenylate cyclase activity were
performed on cell—free homogenates. The main reason
why most studies of beta-adrenoceptor were performed
on membrane preparations instead of intact cells was
related to the difficulty of discriminating the
shereospecific low capacity binding of beta-adrenergic
ligands to receptors from the nonstereospecific high
capacity binding in most mammalian tissues. Tissue
homogenization usually reduces non-specific binding
from 70-80% to 10-20% of the total binding (Porzig
et al., 1982). On the other hand, measuring the
activity of adenylate cyclase in tissue homogenates
suffered from the relatively small magnitude of
stimulated response over the basal activity, thus
making it a less sensitive model to detect changes ofA
the activity of adenylate cyclase after drug treatment
in comparison to the 2 to 3 fold increase in activity
when the assay was performed on brain slices. For
instance, the extent of decrease in the beta-
adrenoceptor coupled adenylate cyclase activity was
about 80-90% of the control, whereas only a 35-40%
decrease was obtained when the assay was performed on
membrane homogenates (Johnson et al. 1978).
In the present study, it was found that the
percentage of decrease in the maximum number of
beta-adrenoceptor as determined by Scatchard analysis
uning vaious concentration of [3H]DHA after 17 days
desipramine treatment was highly correlated with the
decrease in the stimulated activity of adenylate
cyclase in rat cerebral cortex membranes to maximal
effective concentrations of NE (100 uM) and
isoproterenol (10 uM). This is in contrast to the
greater reduction in the activity of NE-stimulated
adenylate cyclase measured in brain slices than the
number of beta-adrenoceptors measured in cerebral
cortex homogenate (Mishra and Sulser, 1980). The
latter difference may be explained by the presence of
spare receptors and that a substantial number of
beta-adrenoceptor are not linked to the adenylate
cyclase. Alternatively, the difference may result from
the use of brain slices for cyclase determination
versus brain homogenates for binding studies. Many
studies have compared quantitatively the
beta-adrenergic agonist binding constants (Kd values)
in cell homogenates with the agonist concentration
required to give half maximal stimulation of adenylate
cyclase (EC50 values). The enzyme was stimulated
either in cell-free homogenates or in intact tissues.
In rat reticulocytes, the preparation of membranes
caused a shift of the EC50 but not the Kd value to
higher agonist concentration. This suggests that the
properties of the beta-receptor-adenylate cyclase
system in the membrane preparations are not identical
to those in the intact cells.
4, 4)Effcct Ql chronic rolipram or desiprarnine
treatment on alpha-adrenoceptor in the rat cerebral
cortex and submandibular gland:
In the present study, it was found that alpha-1
adrenoceptors may be regulated differently (at least
in the temporal sense) in the rat cerebral cortex and
submandibular gland. While the binding of [3H]WB 4101
(1 nM) to alpha-1 adrenoceptor was not altered in
cerebral cortex (table 3.7) it was decreased (about
30-40%) in submandibular glands (table 3.14) after 17
days of rolipram treatment. The decrease of alpha-1
adrenoceptors in submandibular gland was unlikely to
be the result of residual rolipram which may be
present since l)the membranes of submandibular glands
had been washed thoroughly before the binding assay;
2) in vitro rolipram (100 uM) did not affect the
binding of [3H]WB 4101 to the homogenates (table
3.10); 3) the metabolic half life of rolipram is
short. However, the present data did not differentiate
whether the difference in the response to rolipram
treatment in the brain and the submandibular gland is
a time-dependent phenomenon or that. the alpha-1
adrenoceptors are differentially regulated in these
two different tissues.
For the alpha-2 adrenoceptors, it was found that
chronic desipramine treatment for 17 days caused a 20
% decrease in [3H]PAC (1 nM) binding to alpha-2
adrenoceptors in cerebral cortex. Rolipram treatment
for the same period, however, did not alter the
[3H]PAC binding (table 3.9). If the antidepressant
effect of rolipram can be confirmed in the
double-blind clinical trials, then the lack of effect
of chronic rolipram treatment on alpha-2 adrenoceptors
will further support the notion that the adaptative
changes of alpha-2 adrenoceptors is varied and
probably not a common consequence of antidepressive
treatments (Charney et al. 1981; Sugrue, 1981). A
significant decrease (approx. 30%) in
beta-adrenocptors was observed after 11 days of
desipramine treatment, whereas that of the alpha-2
adrenoceptor remained unchanged until 17 days after
desipramine treatment. This may imply that the alpha-2
adrenoceptors in the cerebral cortex are more
resistant to changes than the beta—adrenoceptors.
CONCLUSXON
Neurochemical1y, down-regulation o-f norepi nephr i ne
NE) or isoproterenol-stimulated adenylate cyclase is
commonly associated with various -forms of effective
antidepressive treatments, including the tricyclics,
MAOI and electroconvulsive shock. Frequently, the
down-regulation of NE-coupled adenylate cyclase is
accompanied by a down-regulation of central
beta-adrenoceptors. Moreover, these biochemical
changes are temporally correlated with the onset of
therapeutic efficacy of antidepressive treatments in
A
humans.
In the present study, chronic treatment with
«
rolipram did not change the NE or
isoproterenol-stimulated activity of adenylate cyclase
in the frontal cerebral cortex homogenates of rats.
Moreover, the number (Bmax) as well as the affinity
(Kd) of [3H]DHA of cerebral cortical
beta-adrenoceptors labelled with [3H]DHA were also
unchanged. If the antidepressive effects of rolipram
cannot be confirmed by the double-blind clinical
trials currently being undertaken, then the lack of
effect of rolipram on the beta-adrenoceptors and the
NE-coupled adenylate cyclase is perhaps not
surprising. However, if the antidepressive effects of
rolipram is established subsequently, the present
finding will add to the increasing challenge against
the down-regulation of NE-1inked adenylate cyclase as
a common mechanism of antidepressive treatment.
The cerebral cortex alpha adrenoceptors were
unchanged by chronic rolipram treatment of rats.
However, the same drug treatment decreased
significantly (30- 40%) the alpha-1 adrenoceptors in
the submandibular glands. It seems that the alpha-1
adrenoceptors may be regulated differently in these 2
tissues.
v
After chronic desipramine treatment, the
adaptative changes in beta- and alpha-adrenoceptors
were in general agreement with the literature
findings. For instance, the cerebral cortex alpha-1
adrenoceptors labelled with [3H]WB 4101 were unaltered
after chronic desipramine treatment while the alpha-2
adrenoceptors labelled with [3H]PAC were decreased.
Concerning the regulation of alpha-adrenoceptors, the
pattern of changes were similar in the cerebral cortex
and submandibular glands.
After chronic desipramine treatment, the magnitude
of decrease in beta-adrenoceptors was also comparable
both in the rat cerebral cortex and submandibular
glands. This finding may argue against the obligate
requirement for the presence of intact presynaptic
serotonergic neurons for the down-regulation of
central beta-adrenoceptor proposed for the central
nervous system. Alternatively, the beta-adrenoceptors
in the CNS and in the periphery may be regulated
differently.
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